Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid Mite-Mix SCIT in Allergic Rhinoconjunctivitis With/Without Controlled Asthma
2025-521230-29-00Phase 3Authorised
- Sponsor
- LETI Pharma
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Depigoid Mite-Mix in allergic rhinoconjunctivitis (ARC) and asthma (3 arms), sponsored by LETI Pharma. Primary endpoint: Primary: Change in combined symptom and medication score (cSMS) after 12 SCIT doses. Planned start Oct 2026; status: authorised.
02
Drugs
Depigoid Mite-Mix
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2025-521230-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521230-29-00.